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Familial hypercholesterolemia (FH) is a common inherited disorder of metabolism characterized clinically by high
levels of low-density lipoprotein (LDL) in plasma owing to reduced catabolism. This leads to accelerated athero-
sclerosis and thus to an increased risk of coronary heart disease. FH is usually caused by defects in the gene for
either the LDL receptor or apolipoprotein B (apoB), the ligand for the LDL receptor. Elsewhere, we have described
two unrelated patients with phenotypic homozygous FH. Both patients were offspring of consanguineous unions,
and linkage to either the gene for the LDL receptor or the gene for apoB was excluded in both. Their cells in
culture do not degrade LDL, despite the presence of normal surface binding of LDL to the LDL receptor. This
observation suggests that the patients may be homozygous for a defective gene that encodes a component of the
internalization pathway. We first excluded linkage of the defect to known genes for proteins reported to be involved
in internalization of receptors in clathrin-coated pits. We then performed genomewide homozygosity mapping.
Genotyping of 500 polymorphic markers in three affected and seven unaffected members of the first pedigree
showed that recessive hypercholesterolemia in this family is localized to a single chromosomal region on 1p36-
p35. Genotyping of two affected and five unaffected members of the second pedigree provided further evidence of
linkage to this locus, thereby mapping the disease-causing gene to a 12-cM region on chromosome 1p36-p35, with
a combined LOD score of 5.3 in these unrelated families. Identification of the gene in this region may lead to new
insights into the mechanisms of LDL receptor–mediated uptake of LDL by cells and may help to identify further
genetic risk factors for premature atherosclerosis.
Introduction
Familial hypercholesterolemia (FH [MIM 143890]) is an
inherited disorder of metabolism that is characterized
clinically by an increased concentration of low-density
lipoprotein (LDL) cholesterol in the serum, which results
in accelerated atherosclerosis and the deposition of cho-
lesterol in the peripheral tissues. The disease is usually
caused by defects in the gene for the LDL receptor, a
cell-surface protein that mediates the specific and reg-
ulated uptake and degradation of LDL and some other
cholesterol-rich lipoproteins. FH is inherited as an auto-
somal dominant trait and has a gene dosage effect, in
that heterozygous FH patients with one defective copy
of the LDL-receptor gene usually have an LDL choles-
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terol concentration in plasma that is twofold higher than
normal, whereas homozygous FH patients frequently
have an LDL level that is fivefold higher than normal.
If left untreated, many heterozygous FH patients develop
xanthomas and show signs of coronary heart disease by
early middle age, whereas all homozygous FH patients
have these manifestations of the disease, as well as aortic
root disease, beginning in early childhood (Goldstein et
al. 1995). A defect in the gene for apolipoprotein B
(apoB), which is the major protein component of LDL
and is also the ligand for the LDL receptor, results in a
similar, but generally less severe, phenotype (Myant
1993). However, in studies conducted in various geo-
graphical regions, careful genetic analysis of FH patients
has failed to reveal a defect in the genes for the LDL
receptor or apoB, suggesting that defects in other genes
can result in severe inherited hypercholesterolemia
(Sun et al. 1994; Miserez and Keller 1995; Day et al.
1997).
We have described elsewhere two unrelated patients,
one of Turkish and the other of Asian Indian origin,
with a clinical diagnosis of homozygous FH that is
clearly not due to defects in the genes for the LDL re-
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Table 1
Chromosomal Localization of Genes for Protein
Components of Clathrin-Coated Pits and Clathrin
Adapter Complex 2
Protein Gene
Chromosomal
Localizationa
Clathrin heavy chain-1 CLTC 17q11-qter
Clathrin heavy chain-2 CLTC2 22q11.2
Clathrin light chain-A CLTA 12q23-24
Clathrin light chain-B CLTB 4q2-q3
AP2 large subunit (b1) AP2B1 17q11.2-17q12
AP2 large subunit (a1) AP2A1 19q13.3
AP2 medium subunit (m2) AP2M1 3q28
AP2 small subunit (j2) AP2S1 19q13.2-13.3
Disabled-1 (Dab-1) DAB1 1p31-32
a From the Human Genome Database.
ceptor or apoB (Norman et al. 1999). In both patients,
the disorder appears to be inherited as an autosomal
recessive trait and does not cosegregate with alleles of
the LDL-receptor or apoB genes. In cultured Epstein-
Barr virus–transformed lymphoblasts from both pa-
tients, an apparently normal LDL-receptor protein is
synthesized and transported to the cell surface, where
it binds LDL with normal affinity. However, the ligand
is not degraded, apparently because the receptor-ligand
complex is not internalized by the cells, although the
transferrin receptor is internalized normally, a result
suggesting that the internalization defect is specific for
the LDL receptor (Norman et al. 1999). Both probands
are the offspring of consanguineous parents, suggesting
that the affected individuals in each pedigree are likely
to be homozygous for a region of the genome harboring
the same defective gene allele inherited from a common
ancestor.
In this report we describe the results of a genomewide
scan with polymorphic genetic markers. In both pedi-
grees, the same single region of ∼12 cM on chromosome
1 fulfilled the criteria for homozygous inheritance of
alleles in the affected offspring but not their unaffected
siblings, a result suggesting that the disease gene lies in
this region. A preliminary report of some of these data
has been presented elsewhere (Eden et al. 2000).
Subjects and Methods
Patients
The clinical characteristics of the two index patients
in this study have been described in detail elsewhere
(Norman et al. 1999). For the present study, fasting
blood samples were collected from additional mem-
bers of both pedigrees for analysis of plasma lipid and
lipoprotein concentrations and for isolation, by stan-
dard procedures, of genomic DNA from white blood
cells (Maniatis 1989). Informed consent was obtained
from all participants. For estimation of ethnicity-
specific allele frequencies, anonymous DNA samples
from unrelated Turkish individuals ( ) werenp 25
kindly provided by D. Booth; DNA samples from un-
related Asian Indian individuals ( ) were pro-np 25
vided by B. Knight.
Genotyping
The genomewide screen was performed with a com-
bination of both the Human Genome Mapping Project
(HGMP)/Todd marker set (Reed et al. 1994) and the
ABI PRISM Linkage Mapping Set, version 2 (PE Bio-
systems), which are selected from the Ge´ne´thon human
linkage map (Dib et al. 1996). Amplification conditions
were optimized for each primer pair in a 5-ml reaction
with a Perkin-Elmer 9600 thermal cycler. Pooled PCR
products were separated by electrophoresis on 6% poly-
acrylamide gels on an ABI 377 DNA sequencer (Applied
Biosystems). Alleles were sized by GENESCAN, version
2.1.1, and were scored with GENOTYPER software,
version 2.0 (PE Biosystems), with respect to 6-carboxy
x-rhodamine (for Linkage Mapping Set 2) and 6-car-
boxy tetramethylrhodamine (for the HGMP/Todd set)
500 size standards. After linkage analysis of the genome-
wide data, saturation mapping of candidate regions in-
cluded additional markers selected from the Ge´ne´thon
human linkage map (Dib et al. 1996) or from the Genetic
Location Database (LDB); primers for the latter were
kindly provided by R. Plomin and colleagues. Interloci
mapping distances were taken from the Ge´ne´thon hu-
man linkage map (Dib et al. 1996) or from the LDB,
relative to other Ge´ne´thon markers on this map.
Data Analysis
We initially performed nonparametric and parametric,
single- and multipoint genomewide linkage analysis, us-
ing GENEHUNTER software (Kruglyak and Lander
1995). GENEHUNTER provides multipoint parametric
LOD-score calculations, nonparametric pedigree anal-
ysis, and maximum-likelihood reconstruction of haplo-
types. In the absence of allele frequencies for specific
ethnic groups, frequencies for marker loci were assumed
to be equal for the initial genomewide scan. However,
for the fine mapping of candidate regions, ethnicity-
specific allele frequencies were derived from 25 DNA
samples from the Turkish population (for pedigree 1)
and 25 DNA samples from the Indian population (for
pedigree 2). Parametric analyses were performed assum-
ing an autosomal recessive model of inheritance with
98% penetrance and a disease-allele frequency of .002.
The FASTLINK program LINKMAP (Cottingham et
al. 1993) was also used for multipoint linkage analysis
of markers on selected chromosomes, under the same
model of inheritance. All LOD scores shown in the
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Figure 1 Pedigrees of families with autosomal recessive hyper-
cholesterolemia not caused by mutations in the LDL-receptor gene.
The pretreatment plasma cholesterol concentration (mM/l) of each
individual is indicated below each symbol; the plasma cholesterol level
for individual 14 in pedigree 1 was reported to be in the normal range.
Symbols enclosing dotted lines indicate affected individuals, and sym-
bols containing numbers indicate individuals who were included in
the genetic analysis. Arrows indicate probands.
Table 2
Two-Marker Parametric LOD Scores in Regions Identified
as Potential Candidates on the Basis of a GENEHUNTER
Analysis of the 8-cM Genomewide Map
Chromosomal
Regiona Markersb
Map
Distanceb
(cM)
LOD
Scorec
1p36.2 D1S214–D1S2667 10.5 2.9
1p36-35 D1S199–D1S2734 6.6 1.64
2q21 D2S347–D2S114 10.1 1.06
4q31-32 D4S415–D4S1535 12.4 2.47
5q12-13 D5S424–D5S641 9.5 .19
5q15-21 D5S644–D5S409 6.4 2.23
9q22 D9S387–D9S1690 6.5 .46
12p13 D12S356–D12S336 5.7 .57
14q13 D14S587–D14S75 2.0 1.09
15q26 D15S207–D15S120 6.1 .02
17q12 D17S250–D17S934 4.0 1.04
a Chromosomal regions giving a parametric LOD score.8
after analysis by GENEHUNTER.
b Markers and map distances were taken from the Ge´ne´-
thon human linkage map (Dib et al. 1996).
c Two-marker multipoint parametric LOD scores were cal-
culated by LINKMAP analysis, under an autosomal recessive
mode of inheritance with 98% penetrance.
Results section for both GENEHUNTER and LINK-
MAP are from parametric analyses. The classical LOD-
score threshold of 3 was taken as the criterion for link-
age, on the basis that the segregation pattern in pedigree
1 indicated a single-locus etiology. Such a “dense-map
threshold” has been shown to be appropriate for multi-
stage linkage analyses (Kruglyak and Daly 1998).
Results and Discussion
The defect in internalization of the LDL-receptor protein
in cultured lymphoblastoid cells from the two patients
first prompted us to investigate candidate genes for pro-
teins involved in trafficking of other receptors (for re-
view, see Heilker et al. 1999). Receptor-mediated endo-
cytosis of receptors that are located in clathrin-coated
pits is thought to involve binding of the cytoplasmic
domain to the m2 component of adapter protein com-
plex–2 (AP-2), another component of which binds to the
clathrin. However, this has never been demonstrated di-
rectly for the LDL receptor, and we have already shown
that the sequence and expression of m2 in the patients
described here are not different from those in control
subjects (Norman et al. 1999). It has been suggested that
the cytoplasmic tail of the LDL-receptor protein binds
directly to the heavy chain of clathrin (Kibbey et al.
1998). We therefore analyzed the sequence and relative
level of expression of the mRNA for the ubiquitously
expressed heavy chain of clathrin. The cDNA was am-
plified by reverse transcriptase–PCR from total cellular
mRNA, but nucleotide sequencing did not reveal any
sequence variants in the index patients (data not shown).
All other candidate genes for components of AP-2 and
for other clathrin chains (listed in table 1) were excluded
by the pattern of inheritance of polymorphic markers
flanking each gene of interest. It has also been shown
that the cytoplasmic tail of the LDL receptor can interact
with Dab-1 in the yeast two-hybrid system (Tromsdorff
et al. 1998), but linkage of the defect to this gene was
excluded in the families described here.
The search for mutations in or linkage to candidate
genes was not fruitful, and we therefore decided to
screen for regions of the genome where only the affected
individuals shared homozygosity. A preliminary screen
with 500 highly polymorphic microsatellite markers,
spaced at average intervals of 8 cM, was performedwith
DNA from the 10 individuals indicated in the family
tree of pedigree 1, shown in figure 1. This revealed no
markers with shared homozygosity restricted to the
three affected individuals, and some markers were un-
informative in this pedigree, because the parents were
homozygous at the locus, although typing of a small
percentage of markers was not of sufficient quality. To
achieve the desired ∼8-cM map density, additional
markers from the Ge´ne´thon human linkage map were
typed. At this stage, a single marker (D1S2734 at 1p35)
fulfilled the criteria for homozygosity mapping in the
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Figure 2 Haplotypes for the region of homozygosity on chromosome 1p36-35. Haplotypes for individuals in pedigrees 1 and 2, with the
affected individuals shown as filled symbols, were as constructed by GENEHUNTER (Kruglyak and Lander 1995); the approximate genetic
distances between the markers were taken from the Ge´ne´thon human linkage map (Dib et al. 1996) or from the LDB. Markers accompanied
by an asterisk (*) were taken from the LDB and are shown on the left of the markers. Boxes indicate the region of homozygosity in affected
individuals. Also indicated is the region on chromosome 1p32 that has been mapped in pedigrees with autosomal dominant hypercholesterolemia
(Hunt et al. 2000; Varret el al. 1999).
pedigree (Lander and Botstein 1987). Analysis of the
genomewide scan data by GENEHUNTER, under an
autosomal recessive model of inheritance with 98%
penetrance, resulted in a parametric LOD score 12.0
for two regions, on chromosomes 1p35 ( )LODp 2.4
and 12p13 ( ). Additional regions in whichLODp 2.5
the parametric LOD score was 0.8 were observed on
chromosomes 1, 2, 4, 5, 9, 14, 15, and 17. However,
the size of the pedigree that can be analyzedwithGENE-
HUNTER software is restricted because of software lim-
itations (Kruglyak and Lander 1995). Thus, informa-
tion from only one of the unaffected siblings in the
youngest generation of pedigree 1 could be included in
these GENEHUNTER analyses, and data from individ-
uals 15, 16, and 18 were disregarded. Inspection of the
genotypes for the putative candidate regions in the ped-
igree revealed that, with the exception of the region on
chromosome 1, the haplotypes shared by at least two
of the three affected individuals were not restricted to
affected individuals in the pedigree, because they were
also shared by at least one unaffected sibling. On chro-
mosome 1, only the three affected individuals shared
the same haplotype in the region and were homozygous
for one of the markers (D1S2734). We confirmed this
by performing two-point analysis of the markers in
these putative candidate regions, using the LINKMAP
component of the FASTLINK program (Cottingham et
al. 1993), which permits inclusion of all family mem-
bers. This analysis showed that, when all the unaffected
sibs were included, only chromosome 1 produced a
LOD score 11.0 (table 2).
When the genomewide screen was performed on
seven individuals in pedigree 2 (figure 1), many more
markers were uninformative, a result that may reflect a
greater degree of consanguinity in this pedigree. How-
ever, the two affected siblings were again homozygous
at D1S2734 (although not for the same allele as in ped-
igree 1), and no unaffected members shared this geno-
type. In pedigree 2, one other region on chromosome
9q21-q22 also fulfilled the criteria for homozygosity
mapping; however, this region was excluded in pedigree
1, because the two affected siblings had inherited dif-
Eden et al.: Recessive FH Maps to 1p36-35 657
Figure 3 Linkage of the defect to chromosome 1p36-1p35. Par-
ametric LOD scores for linkage on chromosome 1 were determined
by GENEHUNTER (Kruglyak and Lander 1995), under an autosomal
recessive model of inheritance in which it was assumed that the disease
phenotype was 98% penetrant and that the disease-gene frequency
was .002. Pedigree 1, solid line; pedigree 2, dashed line. Individuals
15, 16, and 18 in pedigree 1 could not be included because of the
constraints of the software.
Figure 4 Combined LOD scores obtained in a genomewide screen with polymorphic markers in pedigrees 1 and 2. A genomewide screen,
with markers located at ∼8-cM intervals, was performed for the individuals as indicated in figure 1. Combined LOD scores were determined
by GENEHUNTER analysis, but individuals 15, 16, and 18 in pedigree 1 could not be included because of the limitations of the software. The
linkage analyses were performed under an autosomal recessive model of inheritance in which it was assumed that the disease phenotype was
98% penetrant and that the disease gene frequency was .002.
ferent paternal alleles and because the genotype shared
by one of the affected siblings and the affected cousin
was also shared by an unaffected sibling.
Fine mapping with markers spaced at ∼1-cM intervals
across the region of interest on chromosome 1 revealed
a 12-cM region of homozygosity shared by all three
affected individuals in pedigree 1 and also revealed a
larger overlapping region of homozygosity in the two
affected siblings in pedigree 2 (fig. 2). However, the
haplotype of the putative mutant allele was different in
the two pedigrees, which is not surprising because the
families are of different racial origin and are therefore
unlikely to share a common founder. When the data
were analyzed by GENEHUNTER, peak parametric
LOD scores of 2.83 in pedigree 1 and 1.51 in pedigree
2 were observed at D1S2725 (fig. 3), giving a combined
LOD score of 4.34. No combined LOD score 11.5 was
observed elsewhere in the genome (fig. 4). As described
above, information from only one of the unaffected in-
dividuals in pedigree 1 could be included in the GENE-
HUNTER analysis of all the markers on chromosome
1, but the observed LOD scores for these individuals
under this model of inheritance approached the maxi-
mum possible values of 3.09 for pedigree 1 and 2.13
for pedigree 2. Under the same model of inheritance, a
three-locus (D1S2843, D1S2725, and D1S2864) multi-
point analysis of the whole family, using FASTLINK,
produced a LOD score at D1S2864 of 3.26 in pedigree
1 and 2.08 in pedigree 2. Again, these results ap-
proached the theoretical maximum values, assuming a
fully informative marker of 3.47 for pedigree 1 and of
2.13 for pedigree 2.
Three recent studies have described genome mapping
in families of index patients who had a clinical diagnosis
of inherited hypercholesterolemia but in whom linkage
to the genes for the LDL receptor and apoB had been
excluded. In two of these studies, inheritance of auto-
somal dominant hypercholesterolemia, with a clinical
diagnosis of typical heterozygous FH, was mapped to
chromosome 1p32 in a single large pedigree from Utah
(Haddad et al. 1999; Hunt et al. 2000) and to 1p34.1-
p32 in a group of 13 families of western European origin
(Varret et al. 1999). The region of overlap on chro-
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Figure 5 Exclusion of homozygosity in pedigrees 1 and 2 on chromosome 15q25-q26. Genotyping was performed with markers spanning
a region on chromosome 15 that has recently been mapped in Sardinian families with a variant form of inherited autosomal recessive hyper-
cholesterolemia (Ciccarese et al. 2000); the markers that delineate the 16-cM region of linkage on 15q25-q26 in that study are underlined. X
indicates recombination events.
mosome 1 in these two studies is ∼6 cM, lying between
D1S2130 and D1S197, and is adjacent to, but clearly
does not overlap, the region of chromosome 1 identified
in the present study (fig. 3). The affected offspring in
the present study were heterozygous for markers
throughout the region identified in the families from
Utah and France. Furthermore, the phenotype in the
patients described here is apparently recessive, and it
therefore differs from that in the patients in these two
studies, although it is known that the penetrance of
hypercholesterolemia in heterozygous FH can vary in
different populations, even in individuals with the same
gene mutation (Sun et al. 1994; Pimstone et al. 1998).
Although we cannot exclude the possibility that in other
environments some individuals heterozygous for the de-
fective gene that we are seeking may be hypercholester-
olemic, there is clearly a strong gene dosage effect in
these two families, as is found in patients with FH due
to mutations in the LDL-receptor gene (Goldstein et
al. 1995). Interestingly, Varret and coworkers (1999)
did not find linkage to their chromosome 1 locus
in all the families tested, a result they interpreted
as evidence for other genetic loci predisposing to
hypercholesterolemia.
In the third study, mapping was performed in several
Sardinian families of index patients who had a clinical
phenotype of homozygous FH but did not have a defect
in the LDL-receptor gene and whose cells in culture
exhibited what appeared to be completely normal LDL-
receptor activity. However, whole-body scans with la-
beled LDL showed that in vivo uptake of LDL by the
liver was reduced, a result that led the authors to suggest
that the genetic defect might be restricted to hepatic
uptake of LDL (Zuliani et al. 1995). Genome mapping
revealed linkage, with a LOD score of 4.0, to a 16-cM
region on chromosome 15, although there did not ap-
pear to be a common haplotype carrying the putative
disease gene in this relatively isolated population (Cic-
carese et al. 2000). Again, the phenotype in the Sardin-
ian families appears to differ from that in the pedigrees
reported here, because we observed impaired internal-
ization of an apparently normal LDL-receptor protein
by cells in culture. We were unable to detect any linkage
to chromosome 15 in the families reported here (as
shown in fig. 5). Although the two siblings in pedigree
1 were homozygous for markers in this region, one of
the unaffected siblings was also homozygous, and their
affected cousin had inherited different alleles at this lo-
cus. In pedigree 2, the two affected siblings had inherited
different paternal alleles in this region. Thus, our data
exclude linkage of a recessive disorder to this locus in
both families.
We conclude that the gene defect in the families de-
scribed here has not been mapped previously and is
likely to lie in the 1p36-35 region of chromosome 1. In
pedigree 2, the computed linkage to this region was not
as strong, because there were only two affected indi-
viduals and the family was much smaller. As stated
above, the two families are unlikely to share a common
ancestor; however, the clinical phenotype of the affected
individuals is similar, as is the defect in their cells in
culture, and these similarities suggest that they share the
same gene defect. On the other hand, the affected in-
dividuals could equally well have defects in different
genes whose protein products lie on the same cellular
pathway, thereby resulting in the same phenotype. Nor
can we formally exclude, at this stage, the possibility
that the phenotype in the families described here has
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arisen as the result of interaction between two or more
gene variants. Resolution of these issues awaits the iden-
tification and characterization of the gene concerned.
We have not yet identified any strong candidate genes
in the region of 1p36-35, but the full genome sequence
of this region is not available (Sanger Centre Chromo-
some 1 web site). Since cells from the affected individ-
uals exhibit deficient internalization of LDL, analysis of
differential expression of mRNA or protein in these cells
compared with cells from normolipemic controls may
assist in the identification of the defective gene.
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